RecruitingPHASE1, PHASE2NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kartos Therapeutics, Inc.
- Intervention
- KRT-232(drug)
- Enrollment
- 109 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (26)
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Texas Oncology- Sammons CC at Baylor, Dallas, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- Centre Leon Berard, Lyon, France
- APHM Hopital de la Timone, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
- Centre Hospitalier Lyon Sud, Saint-Genis-Laval, France
- Policlinico di Milano Ospedale Maggiore | Fondazione IRCCS Ca' Granda, Milan, MI, Italy
- Azienda Ospedaliero - Universitaria Mater Domini, Catanzaro, Italy
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola FC, Italy
- Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Pratia Onkologia Katowice, Katowice, Poland
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04835584 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics